What is it about?
Malignant glioma is a very fatal form of brain tumor, representing 81% of malignant brain tumors and has a 5-year relative survival of ∼5%. Glioblastoma multiforme (GBM), the stage IV glioma is a devastating brain cancer that typically results in death in the first 15 months after diagnosis. Onset and progression of gliomas is accompanied by severe debilitation of T-cell defense and T-cell survival. The novel immune potentiator T11TS enhances the immune system profoundly retarding glioma growth in rat model. T cells are pivotal cells of the immune system playing a major role in the eradication of glioma.Glioma restrain T cell proliferation, so dampens the fight against glioma. But T11TS invigorates Tcell activation and proliferation so that glioma is overpowered. T cells can accomplish this by various pathways. One of the chief contributors to T-cell survival downstream of activation is the PI3K-AKT pathway, which has been dealt in this article. Results showed heightened activation of the PI3K-AKT pathway in glioma-bearing rats following T11TS immunotherapy. These results illustrate the novel role of T11TS immunotherapy in ameliorating the PI3K pathway in T-cells in glioma-bearing animals to enhance T-cell survival, according greater defense against glioma.
Featured Image
Why is it important?
The study thus has far-reaching clinical outcomes.
Perspectives
This publication is unique, as it shows how a novel immunomodulator T11TS can repair the glioma generated damage in the T cell survival pathway ie., the PI3K-AKT pathway so that the revived T cells can fight against glioma to eradicate them.
Swapna Chaudhuri
Read the Original
This page is a summary of: T11TS immunotherapy repairs PI3K-AKT signaling in T-cells: Clues toward enhanced T-cell survival in rat glioma model, Journal of Cellular Physiology, July 2017, Wiley,
DOI: 10.1002/jcp.26047.
You can read the full text:
Contributors
The following have contributed to this page
